115 related articles for article (PubMed ID: 23245845)
1. The role of adipose tissue-associated macrophages and T lymphocytes in the pathogenesis of inflammatory bowel disease.
Jung SH; Saxena A; Kaur K; Fletcher E; Ponemone V; Nottingham JM; Sheppe JA; Petroni M; Greene J; Graves K; Baliga MS; Fayad R
Cytokine; 2013 Feb; 61(2):459-68. PubMed ID: 23245845
[TBL] [Abstract][Full Text] [Related]
2. Dietary flaxseed oil reduces adipocyte size, adipose monocyte chemoattractant protein-1 levels and T-cell infiltration in obese, insulin-resistant rats.
Baranowski M; Enns J; Blewett H; Yakandawala U; Zahradka P; Taylor CG
Cytokine; 2012 Aug; 59(2):382-91. PubMed ID: 22592037
[TBL] [Abstract][Full Text] [Related]
3. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes.
Woo HM; Kang JH; Kawada T; Yoo H; Sung MK; Yu R
Life Sci; 2007 Feb; 80(10):926-31. PubMed ID: 17196622
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells.
Linehan JD; Kolios G; Valatas V; Robertson DA; Westwick J
Free Radic Biol Med; 2005 Dec; 39(12):1560-9. PubMed ID: 16298681
[TBL] [Abstract][Full Text] [Related]
5. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
[TBL] [Abstract][Full Text] [Related]
6. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.
Olsen T; Rismo R; Cui G; Goll R; Christiansen I; Florholmen J
Cytokine; 2011 Dec; 56(3):633-40. PubMed ID: 21945121
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease.
Nielsen OH; Kirman I; Rüdiger N; Hendel J; Vainer B
Scand J Gastroenterol; 2003 Feb; 38(2):180-5. PubMed ID: 12678335
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
9. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production.
Zeyda M; Farmer D; Todoric J; Aszmann O; Speiser M; Györi G; Zlabinger GJ; Stulnig TM
Int J Obes (Lond); 2007 Sep; 31(9):1420-8. PubMed ID: 17593905
[TBL] [Abstract][Full Text] [Related]
10. Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis.
Clemente TR; Dos Santos AN; Sturaro JN; Gotardo EM; de Oliveira CC; Acedo SC; Caria CR; Pedrazzoli J; Ribeiro ML; Gambero A
Scand J Gastroenterol; 2012 Sep; 47(8-9):943-50. PubMed ID: 22630819
[TBL] [Abstract][Full Text] [Related]
11. Cytokines in inflammatory bowel disease.
Kmieć Z
Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
[TBL] [Abstract][Full Text] [Related]
12. Immune mechanisms in chronic inflammatory bowel disease.
Braegger CP; MacDonald TT
Ann Allergy; 1994 Feb; 72(2):135-41. PubMed ID: 8109803
[TBL] [Abstract][Full Text] [Related]
13. [Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases].
Blázovics A; Hagymási K; Prónai L
Orv Hetil; 2004 Dec; 145(50):2523-9. PubMed ID: 15662752
[TBL] [Abstract][Full Text] [Related]
14. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
15. Effects of methotrexate on inflammatory alterations induced by obesity: an in vivo and in vitro study.
DeOliveira CC; Acedo SC; Gotardo EM; Carvalho Pde O; Rocha T; Pedrazzoli J; Gambero A
Mol Cell Endocrinol; 2012 Sep; 361(1-2):92-8. PubMed ID: 22480543
[TBL] [Abstract][Full Text] [Related]
16. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis.
Gonzalez-Rey E; Anderson P; González MA; Rico L; Büscher D; Delgado M
Gut; 2009 Jul; 58(7):929-39. PubMed ID: 19136511
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
19. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.
Sakata A; Ochiai T; Shimeno H; Hikishima S; Yokomatsu T; Shibuya S; Toda A; Eyanagi R; Soeda S
Immunology; 2007 Sep; 122(1):54-64. PubMed ID: 17451462
[TBL] [Abstract][Full Text] [Related]
20. Allium sativum (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease.
Hodge G; Hodge S; Han P
Cytometry; 2002 Aug; 48(4):209-15. PubMed ID: 12210145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
